Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.36 |
---|---|
High | 9.36 |
Low | 9.36 |
Bid | 8.69 |
Offer | 8.89 |
Previous close | 9.36 |
Average volume | -- |
---|---|
Shares outstanding | 54.43m |
Free float | 52.09m |
P/E (TTM) | -- |
Market cap | 40.28m USD |
EPS (TTM) | -0.526 USD |
Data delayed at least 15 minutes, as of Jun 09 2020.
More ▼
Announcements
- CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
- CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
- CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
- FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
- CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
More ▼